Table 2.
NTMs among the new TB patients and five MDR-TB high-risk suspect group, % (NTMs number/screening number)*
| Items | New patients | MDR-TB high-risk suspect groups | Total | ||||
|---|---|---|---|---|---|---|---|
| Group 1* | Group 2* | Group 3* | Group 4* | Group 5* | |||
| Total | 3.1 (300/9830) | 3.7 (7/187) | 4.4 (15/338) | 4.8 (13/273) | 5.4 (10/184) | 8.1 (113/1390) | 3.8 (458/12202) |
| Age (years) | |||||||
| 0–29 | 1.4 (33/2338) | 0 (0/38) | 1.1 (1/89) | 0 (0/41) | 0 (0/26) | 2.5 (4/160) | 1.4 (38/2692) |
| 30–60 | 2.3 (88/3865) | 2.7 (2/73) | 4.7 (7/148) | 4.0 (6/150) | 4.6 (4/87) | 6.5 (40/620) | 3.0 (147/4943) |
| >60 | 4.9 (179/3627) | 6.6 (5/76) | 6.9 (7/101) | 8.5 (7/82) | 8.5 (6/71) | 11.3 (69/610) | 6.0 (273/4567) |
| Sex | |||||||
| Male | 2.8 (195/6935) | 3.4 (5/146) | 3.6 (9/247) | 3.2 (7/222) | 5.4 (8/149) | 7.2 (76/1058) | 3.4 (300/8757) |
| Female | 3.6 (105/2895) | 4.9 (2/41) | 6.6 (6/91) | 11.8 (6/51) | 5.7 (2/35) | 11.1 (37/332) | 4.6 (158/3445) |
| Area | |||||||
| Hangzhou | 4.0 (146/3647) | 3.4 (4/117) | 3.1 (8/256) | 4.7 (9/193) | 6.7 (8/120) | 10.3 (74/718) | 4.9 (249/5051) |
| Huzhou | 1.8 (19/1063) | 0 (0/4) | 4.3 (1/23) | 2.6 (1/38) | 8.0 (2/25) | 5.2 (7/135) | 2.3 (30/1288) |
| Shaoxing | 3.4 (69/2028) | 0 (0/7) | 25 (3/12) | 7.7 (1/13) | 0 (0/9) | 6.7 (16/238) | 3.9 (89/2307) |
| Jiaxing | 9.8 (47/480) | 4.9 (2/41) | 16.7 (2/12) | 0 (0/3) | 0 (0/2) | 14.0 (7/50) | 9.9 (58/588) |
| Quzhou | 1.2 (19/1603) | 6.7 (1/15) | 3.8 (1/26) | 14.3 (2/14) | 0 (0/16) | 5.1 (9/176) | 1.7 (32/1850) |
| Lishui | 0 (0/1009) | 0 (0/3) | 0 (0/9) | 0 (0/12) | 0 (0/12) | 0 (0/73) | 0 (0/1118) |
| Year | |||||||
| 2009 | 0 (0/3) | 0 (0/0) | 0 (0/31) | 0 (0/38) | 0 (0/10) | 0 (0/33) | 0 (0/115) |
| 2010 | 0 (0/150) | 0 (0/9) | 0 (0/31) | 0 (0/65) | 0 (0/5) | 0 (0/82) | 0 (0/342) |
| 2011 | 2.0 (55/2784) | 3.1 (2/64) | 5.2 (5/97) | 10.8 (7/65) | 5.0 (3/60) | 6.2 (24/387) | 2.8 (96/3457) |
| 2012 | 3.3 (115/3433) | 6.8 (3/44) | 5.5 (5/91) | 4.7 (2/43) | 9.1 (6/66) | 9.0 (40/444) | 4.1 (171/4121) |
| 2013 | 3.8 (130/3460) | 2.9 (2/70) | 5.7 (5/88) | 6.5 (4/62) | 2.3 (1/43) | 11.0 (49/444) | 4.6 (191/4167) |
*Group 1: New cases persisting sputum culture or smear positive at the end of the 2nd month after treatment; Group 2: New cases of initial treatment failure; Group 3: Re-treatment cases of treatment failure; Group 4: Cases with poor treatment compliance: patients receiving treatment and interruption and re-treatment again; Group 5: Recurrence cases. MDR: Multidrug resistant; TB: Tuberculosis; NTMs: Nontuberculosis mycobacteria.